{"nctId":"NCT02842853","briefTitle":"Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine","startDateStruct":{"date":"2016-07-15","type":"ACTUAL"},"conditions":["Meningitis","Meningococcal Meningitis","Meningococcal Infections"],"count":3344,"armGroups":[{"label":"MenACYW Conjugate Vaccine Lot 1","type":"EXPERIMENTAL","interventionNames":["Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine"]},{"label":"MenACYW Conjugate Vaccine Lot 2","type":"EXPERIMENTAL","interventionNames":["Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine"]},{"label":"MenACYW Conjugate Vaccine Lot 3","type":"EXPERIMENTAL","interventionNames":["Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine"]},{"label":"Menactra®","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine"]}],"interventions":[{"name":"Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine","otherNames":["MenACYW conjugate vaccine"]},{"name":"Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine","otherNames":["Menactra®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged 10 to 55 years on the day of inclusion.\n* Informed consent form was signed and dated by the participant (aged 18 to 55 years) or assent form was signed and dated by the participant and informed consent form was signed and dated by the parent(s) or guardian (for participants aged 10 to \\< 18 years).\n* Participant (\\>= 18 years) or participant (10 to \\< 18 years) and parent / guardian were able to attend all scheduled visits and comply with all trial procedures.\n\nExclusion Criteria:\n\n* Participant was pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must have been pre-menarche or post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination).\n* Participation in the 4 weeks preceding the trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.\n* Receipt of any vaccine in the 4 weeks (28 days) preceding the trial vaccination or planned receipt of any vaccine prior to Visit 2 except for influenza vaccination, which may be received at least 2 weeks before or after the study investigational vaccines. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines.\n* Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine (i.e., mono- or polyvalent, polysaccharide, or conjugate meningococcal vaccine containing serogroups A, C, Y, or W; or meningococcal B vaccine).\n* Receipt of immune globulins, blood or blood-derived products in the past 3 months.\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).\n* History of meningococcal infection, confirmed either clinically, serologically, or microbiologically.\n* At high risk for meningococcal infection during the trial (specifically, but not limited to, participants with persistent complement deficiency, with anatomic or functional asplenia, or participants traveling to countries with high endemic or epidemic disease).\n* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances.\n* Verbal report of thrombocytopenia, as reported by the participant or the participant's parent / guardian, contraindicating intramuscular vaccination in the Investigator's opinion.\n* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination in the Investigator's opinion.\n* Personal history of Guillain-Barre syndrome.\n* Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid-containing vaccine within 10 years of the proposed study vaccination.\n* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.\n* Current alcohol abuse or drug addiction.\n* Chronic illness that, in the opinion of the Investigator, was at a stage where it might interfere with trial conduct or completion.\n* Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature \\>= 100.4 degree Fahrenheit \\[°F\\]). A prospective participant was not be included in the study until the condition was resolved or the febrile event had subsided.\n* Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw.\n* Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"10 Years","maximumAge":"55 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Meningococcal Serogroups A, C, Y, And W Antibodies Following Vaccination With 3 Lots of MenACYW Conjugate Vaccine","description":"Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by serum bactericidal assay using human complement (hSBA). Data for this outcome measure were not planned to be collected and analyzed for the Menactra® reporting group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.9","spread":null},{"groupId":"OG001","value":"96.5","spread":null},{"groupId":"OG002","value":"97.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"326","spread":null},{"groupId":"OG001","value":"305","spread":null},{"groupId":"OG002","value":"352","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"213","spread":null},{"groupId":"OG001","value":"210","spread":null},{"groupId":"OG002","value":"218","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.5","spread":null},{"groupId":"OG001","value":"81.6","spread":null},{"groupId":"OG002","value":"87.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y And W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine","description":"Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \\>= 1:16 for participants with pre-vaccination hSBA titers \\< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers \\>= 1:8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.8","spread":null},{"groupId":"OG001","value":"54.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.8","spread":null},{"groupId":"OG001","value":"47.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.4","spread":null},{"groupId":"OG001","value":"73.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.3","spread":null},{"groupId":"OG001","value":"61.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y And W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine in Adults","description":"Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \\>= 1:16 for participants with pre-vaccination hSBA titers \\< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers \\>= 1:8. Only adults aged 18-55 years who received a single dose of Menactra® (Group 4b) or MenACYW Conjugate vaccine (Group 1b-3b) from any of the lots 1, 2 or 3, were included in this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.5","spread":null},{"groupId":"OG001","value":"53.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.4","spread":null},{"groupId":"OG001","value":"42.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.1","spread":null},{"groupId":"OG001","value":"60.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.0","spread":null},{"groupId":"OG001","value":"50.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y And W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine in Adolescents","description":"Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \\>= 1:16 for participants with pre-vaccination hSBA titers \\< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers \\>= 1:8. Only adolescents aged 10-17 years who received a single dose of Menactra® (Group 4a) or MenACYW Conjugate vaccine (Group 1a-3a) from any of the lots 1, 2 or 3, were included in this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.0","spread":null},{"groupId":"OG001","value":"55.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.6","spread":null},{"groupId":"OG001","value":"53.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.6","spread":null},{"groupId":"OG001","value":"85.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.5","spread":null},{"groupId":"OG001","value":"72.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y And W Following Vaccination With 3 Lots of MenACYW Conjugate Vaccine","description":"Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \\>= 1:16 for participants with pre-vaccination hSBA titers \\< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers \\>= 1:8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.1","spread":null},{"groupId":"OG001","value":"76.5","spread":null},{"groupId":"OG002","value":"73.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.5","spread":null},{"groupId":"OG001","value":"89.1","spread":null},{"groupId":"OG002","value":"86.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.4","spread":null},{"groupId":"OG001","value":"91.9","spread":null},{"groupId":"OG002","value":"89.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.5","spread":null},{"groupId":"OG001","value":"80.7","spread":null},{"groupId":"OG002","value":"78.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs) of Meningococcal Serogroups A, C, Y, and W Antibodies Following Vaccination With MenACYW Conjugate and Menactra®","description":"Antibody titers of meningococcal serogroups A, C, Y, and W were measured by hSBA.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","spread":null},{"groupId":"OG001","value":"48.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"328","spread":null},{"groupId":"OG001","value":"40.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"214","spread":null},{"groupId":"OG001","value":"66.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.4","spread":null},{"groupId":"OG001","value":"44.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":895},"commonTop":["Injection site pain","Myalgia","Headache","Malaise","Injection site erythema"]}}}